A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer-Reference-Cited by-同舟云学术

A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer

Published:2006-08 Issue:3 Volume:7 Page:270-277
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Modi Shanu,D'Andrea Gabriella,Norton Larry,Yao Tzy Jyun,Caravelli James,Rosen Peter P.,Hudis Clifford,Seidman Andrew D.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture;Fitzpatrick;Cancer Res,1984

2. Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels;Fitzpatrick;Cancer Res,1984

3. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients;Klijn;Endocr Rev,1992

4. Cell signalling by receptor tyrosine kinases;Schlessinger;Cell,2000

5. An update on epidermal growth factor receptor inhibitors;Modi;Current Oncol Rep,2002

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: A critical review;Results in Chemistry;2024-01

2. Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions;Clinical Breast Cancer;2023-12

3. Role of Molecular Targeted Therapeutic Drugs in Treatment of Breast Cancer: A Review Article;Global Medical Genetics;2023-05-23

4. Beyond HER2: Targeting the ErbB receptor family in breast cancer;Cancer Treatment Reviews;2022-09

5. Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker;ecancermedicalscience;2022-07-20